Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Astellas Pharma Inc., is a pioneering entity in the field of regenerative medicine, headquartered in the United States. Established in 2007, AIRM focuses on developing innovative cell therapies aimed at addressing unmet medical needs, particularly in the areas of oncology and rare diseases. With a commitment to advancing scientific research, AIRM has achieved significant milestones, including the development of unique cell-based therapies that leverage cutting-edge technology. The institute's core offerings include advanced cell therapy products that stand out for their potential to transform patient outcomes. Recognised for its contributions to the regenerative medicine landscape, AIRM continues to solidify its market position through strategic partnerships and a robust pipeline of therapeutic candidates, driving forward the future of healthcare.
We don't have data for Astellas Institute for Regenerative Medicine, but we can show you information about their parent organization instead.
View parent company